Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma
Cited by 13
Abstract
Related Papers
No related papers found
Powered by citation graph analysis